Plaque Thrombosis is Reduced by Attenuating Plaque Inflammation with Pioglitazone and is Evaluated by Fluorodeoxyglucose Positron Emission Tomography

Summary Introduction The relationship between the beneficial effects of pioglitazone in reducing clinical events and plaque inflammatory burden remains unknown. This study aimed to determine whether pioglitazone can reduce the number of plaque thrombosis incidences and whether decreasing plaque infl...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular therapeutics 2015-06, Vol.33 (3), p.118-126
Main Authors: Zhang, Ming‐Duo, Zhao, Xue‐Cheng, Zhang, Yu‐Hui, Yan, Yun‐Feng, Wang, Zheng‐Ming, Lv, Shu‐Zheng, Zhao, Quan‐Ming
Format: Article
Language:English
Subjects:
Animals
Atherosclerosis
Biomarkers
Blood Glucose
C-Reactive Protein - metabolism
Fluorodeoxyglucose F18
Hypoglycemic Agents - pharmacology
Inflammation - drug therapy
Lipids - blood
Male
Matrix Metalloproteinase 9 - metabolism
Pioglitazone
Plaque, Atherosclerotic - drug therapy
Positron emission tomography or PET
Positron-Emission Tomography
Rabbits
Thiazolidinediones - pharmacology
Thrombosis
Thrombosis - prevention & control
Tomography, X-Ray Computed
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Summary Introduction The relationship between the beneficial effects of pioglitazone in reducing clinical events and plaque inflammatory burden remains unknown. This study aimed to determine whether pioglitazone can reduce the number of plaque thrombosis incidences and whether decreasing plaque inflammation is the mechanism by which pioglitazone reduces plaque thromboses. Methods and Results therosclerotic rabbits were divided into two groups: the atherosclerosis group (n = 13) and pioglitazone group (n = 10). The rabbits underwent pharmacological triggering to induce thrombosis. Serum inflammatory markers, FDG uptake, macrophage, and neovessel staining detected arterial inflammation. PET/CT scans were performed twice (baseline and posttreatment scans). Plaque area, macrophages, and neovessels were measured and the histologic sections were matched with the PET/CT scans. Serum MMP‐9 and hsCRP were lower in the pioglitazone group compared to the atherosclerosis group. The SUVmean significantly decreased in the pioglitazone group (0.62 ± 0.21 vs. 0.55 ± 0.19, P = 0.008), but increased in the atherosclerosis group (0.61 ± 0.15 vs. 0.91 ± 0.20, P 
ISSN:1755-5914
1755-5922
DOI:10.1111/1755-5922.12119